| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MFGE8 |
| Uniprot No | Q08431 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-387aa |
| 氨基酸序列 | LDICSKNPCHNGGLCEEISQEVRGDVFPSYTCTCLKGYAGNHCETKCVEPLGMENGNIANSQIAASSVRVTFLGLQHWVPELARLNRAGMVNAWTPSSNDDNPWIQVNLLRRMWVTGVVTQGASRLASHEYLKAFKVAYSLNGHEFDFIHDVNKKHKEFVGNWNKNAVHVNLFETPVEAQYVRLYPTSCHTACTLRFELLGCELNGCANPLGLKNNSIPDKQITASSSYKTWGLHLFSWNPSYARLDKQGNFNAWVAGSYGNDQWLQVDLGSSKEVTGIITQGARNFGSVQFVASYKVAYSNDSANWTEYQDPRTGSSKIFPGNWDNHSHKKNLFETPILARYVRILPVAWHNRIALRLELLGC |
| 预测分子量 | 56.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MFGE8重组蛋白的3篇代表性文献示例(内容为虚构，供参考)：
---
1. **文献名称**: *Recombinant MFGE8 Attenuates Inflammation by Promoting Efferocytosis in Sepsis*
**作者**: Zhang L, et al.
**期刊**: *Nature Immunology* (2022)
**摘要**: 研究证明重组MFGE8蛋白通过增强巨噬细胞对凋亡细胞的吞噬作用(efferocytosis)，显著降低脓毒症模型小鼠的全身炎症反应，并提高生存率，提示其作为抗炎治疗的潜在价值。
---
2. **文献名称**: *MFGE8 Recombinant Protein Enhances Tissue Repair in Myocardial Infarction*
**作者**: Tanaka K, et al.
**期刊**: *Circulation Research* (2020)
**摘要**: 通过在小鼠心肌梗死模型中注射重组MFGE8蛋白，研究发现其通过激活整合素信号通路促进血管新生和心肌细胞存活，显著改善心脏功能。
---
3. **文献名称**: *Role of Recombinant MFGE8 in Suppressing Tumor Metastasis via αvβ3 Integrin Inhibition*
**作者**: Chen X, et al.
**期刊**: *Cell Reports* (2019)
**摘要**: 体外和体内实验表明，重组MFGE8通过竞争性结合αvβ3整合素阻断肿瘤细胞与细胞外基质的相互作用，抑制乳腺癌转移，为癌症靶向治疗提供新思路。
---
4. **文献名称**: *MFGE8 Recombinant Protein Reverses Insulin Resistance in Obesity Models*
**作者**: Gupta R, et al.
**期刊**: *Diabetes* (2021)
**摘要**: 研究显示，肥胖小鼠模型中重组MFGE8蛋白通过调节脂肪组织巨噬细胞极化，改善胰岛素敏感性，为代谢综合征治疗提供实验依据。
---
(注：以上文献为示例，实际研究中需根据具体需求检索真实数据库如PubMed或Web of Science。)
Milk fat globule-epidermal growth factor 8 (MFGE8), also known as lactadherin, is a secreted glycoprotein that plays multifaceted roles in physiological and pathological processes. Initially identified in breast milk and mammary epithelial cells, it is widely expressed in various tissues, including vascular endothelium, macrophages, and epithelial cells. Structurally, MFGE8 contains two N-terminal epidermal growth factor (EGF)-like domains, which mediate binding to integrins (e.g., αvβ3/β5), and a C-terminal discoidin-like domain that interacts with phosphatidylserine on apoptotic cells or exposed phospholipids on damaged tissues.
Functionally, MFGE8 acts as a bridging molecule, facilitating the clearance of apoptotic cells via phagocytosis (efferocytosis) and modulating immune responses. It also promotes angiogenesis, tissue remodeling, and cell adhesion by activating integrin-dependent signaling pathways. Dysregulation of MFGE8 has been implicated in inflammatory diseases (e.g., atherosclerosis, lupus), tissue fibrosis, and cancer progression. In tumors, MFGE8 can enhance metastasis by supporting vascularization, immune evasion, and epithelial-mesenchymal transition.
Recombinant MFGE8 protein, produced through expression systems like mammalian or bacterial cells, retains these functional domains and is widely used to study cellular mechanisms in vitro and in vivo. Its therapeutic potential is being explored in contexts such as enhancing tissue repair, mitigating inflammation, or blocking pathological interactions in cancer. Conversely, inhibitors targeting MFGE8-integrin interactions are under investigation for anti-cancer applications. As a versatile mediator of cell-cell communication, MFGE8 remains a critical focus in translational research bridging immunology, oncology, and regenerative medicine.
×
